Jim Van Meerten's  Instablog

Jim Van Meerten
Send Message
Jim Van Meerten is an advisor to Marketocracy Capital Management and writes on financial subjects here and on Barchart Portfolio Blogs and Seeking Alpha. He earned a BS in Accounting and Business Administration from Berry College; a Juris Doctorate from the Woodrow Wilson School of Law; and... More
My company:
Marketocracy capital management
My blog:
Barchart Portfolio Blogs
  • Profit from Flu vaccines 0 comments
    Sep 24, 2010 11:38 AM | about stocks: SNY

    This morning I added Sanofi-Aventis (NYSE:SNY) to the Barchart Van Meerten New High portfolio  They are a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated health care solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of health care products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (NYSE:CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.

    Two of the drugs they produce are two of the most widely marketed drugs on the planet.  The A/H1N1 flu vaccine and Plavix.  I can't watch an evening of TV without seeing several Plavix commercials.  Since I had my flu shot my cravings for corn and mud baths are now under control.

    The stock is on a recent climb with 19 new highs in 20 session for a 19.82% price gain last month.  Barchart has a 96% buy signal with the stock trading around 33.95 above its 50 day high of 30.27.  The stock has a 76.93% 14 day Relative Strength Index and is rising.

    General investor sentiment is high with the CAPS members on Motley Fool voting 882 to 41 that the stock will beat the market and the All Stars are in agreement 329 to 11.  The Wall Street columnists that Fool follows had 14 positive articles on the stock.

    Their major markets of the US and Europe means they are marketing in an area of both public and private health care that can afford their products.  With all the recent interest in flu vaccines and diabetes drugs this stock should be a winner.

    Jim Van Meerten is an advisor to Marketocracy Capital Management who uses his model portfolios not only to manage their mutual funds but also their clients Separately Managed Accounts. You can read his blogs about those model portfolios and investing here and on Barchart Portfolio Blogs. Please leave a comment below or email mailto:JimVanMeerten@gmail.com


    Disclosure: Jim Van Meerten through Marketocracy Capital Management has an interest in the stocks mentioned in this blog.

    Disclosure: I have an interest in this stock

    Stocks: SNY
Back To Jim Van Meerten's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • $EXEL - 96% technical buy signals - 16 new highs and up 39.23% in the last month = Relative Strength Index 86.09
    2 days ago
  • $FARM = 100% technical buy signals - 19 new highs and up 19.51% in the last month - Relative Strength Index 82.78%
    5 days ago
  • $WIN - 96% technical buy signals - 16 new highs and up 19.76% in the last month - Relative Strength index 75.56%
    5 days ago
More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.